Infected knee joint
Courtesy of Dr. Donald W. Hohman Jr. Orthopaedic Surgeon
Dallas, TX, USA
45-year-old female presented with 6 months’ history of knee pain and swelling. This patient had undergone allograft reconstruction of the anterior cruciate ligament 9 months prior. X-ray examination indicated bone tunnel widening and reactive changes in the proximal tibia. MRI examination indicated knee joint effusion and signal changes in the tibia and femur marked the presence of osteomyelitis. Inflammatory markers (ESR/CRP) were elevated and aspiration of the knee joint effusion cultured positive for Staphylococcus epidermidis.
Surgical management was elected with extraction of the allograft. Irrigation and debridement of the tibia and femur were carried out to remove all non-viable tissue with removal of all fixation devices. STIMULAN beads were used to fill the tibia defect and genex® was used to fill the femoral defect. A course of intravenous antibiotics was completed based on the sensitivities of the organism.
Pain and swelling resolved post-operatively. Following antibiotic therapy, the infection had cleared clinically 3 months after surgery with normalization of the inflammatory markers and symptomatic improvement.
At 6 months’ follow-up both the STIMULAN and genex were fully absorbed and replaced with bone. Inflammatory markers remained normal. The patient had minimal pain secondary to arthritic changes in the knee.
For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time.
This brochure may include the use of STIMULAN or techniques that go beyond the current clearance / approval granted by the relevant regulatory authority. Please contact your local representative for further information.
©2018, Biocomposites, STIMULAN, Bringing Calcium to Life, Power to Transform Outcomes and DRy26 are trademarks/registered trademarks of Biocomposites Ltd. All rights reserved. No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.
Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 8883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1
Patents pending: GB1502655.2, US 15/040075, CN 201610089710.5, US 15/288328, GB1704688.9, EP 18275044.8, US 15/933936